teaser
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.
Genmab has regained all rights to the HuMax-CD4
